INDICATION: Diabetes
GlycoBien® is designed to provide first-line therapy for both prediabetics and newly diagnosed Type 2 diabetic patients.
GlycoBien® CR is currently in Phase II clinical trial.
The estimated market for GlycoBien® in the United States is $8 Billion USD.
The estimated market for GlycoBien® globally is $10 Billion USD.